X90.F PROBIOTIX HEALTH LS-05
- Market cap
- EUR 16.5M
- P/E
- -
- P/B
- 6.85x
- ROE
- -85.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is X90.F undervalued?
Graham numberThe Graham number of PROBIOTIX HEALTH LS-05 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PROBIOTIX HEALTH LS-05 fundamental analysis
No fundamental analysis for PROBIOTIX HEALTH LS-05 yet.
PROBIOTIX HEALTH LS-05 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and YourBiotixVH for vascular health support. The company was formerly known as ProB…
Full company profilePROBIOTIX HEALTH LS-05 financial statements
PROBIOTIX HEALTH LS-05 annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Income Statement | |||
| Revenue | 1.67M | 1.88M | 2.73M |
| Gross Profit | 872K | 997K | 1.48M |
| Operating Income | -719K | -839K | -1.24M |
| EBITDA | -666K | -771K | -1.18M |
| Net Income | -747K | -847K | -1.23M |
| EPS | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||
| Total Assets | 2.17M | 2.18M | 1.81M |
| Total Liabilities | 641K | 254K | 365K |
| Shareholders' Equity | 1.53M | 1.92M | 1.44M |
| Cash & Short-term Investments | 1.50M | 1.65M | 1.27M |
| Cash Flow | |||
| Operating Cash Flow | -238K | -1.06M | -367K |
| Capital Expenditure | 0.00 | 10.0K | 12.0K |
| Free Cash Flow | -238K | -1.07M | -379K |
| Ratios | |||
| ROE | -48.8% | -44.0% | -85.4% |
| ROA | -34.4% | -38.9% | -68.2% |
| Net Profit Margin | -44.7% | -45.0% | -45.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PROBIOTIX HEALTH LS-05 dividends
PROBIOTIX HEALTH LS-05 has not paid dividends in the last 4 fiscal years.
Who owns PROBIOTIX HEALTH LS-05
- Insiders 29.43%
- Institutions 5.00%
- Public & others 65.57%
- Shares outstanding 158M
- Free float 116M
PROBIOTIX HEALTH LS-05 company profile
- Company name
- PROBIOTIX HEALTH LS-05
- Ticker
- X90.F
- ISIN
- GB00BLNBFR86
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- First Floor Zucchi Suite, Wakefield, United Kingdom, WF4 1AB
- Website
- probiotixhealth.com
About PROBIOTIX HEALTH LS-05
ProBiotix Health Plc develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally. The company offers YourBiotixMH for menopause health; YourBiotixCH InstaMelt and YourBiotixCH for cholesterol maintenance; and YourBiotixX3 for cholesterol reduction. It also provides YourBiotixBP for blood pressure reduction; and YourBiotixVH for vascular health support. The company was formerly known as ProBiotix Health Limited and changed its name to ProBiotix Health Plc in February 2022. The company was founded in 2012 and is based in Wakefield, the United Kingdom.
PROBIOTIX HEALTH LS-05 management
3- Mr. Steen Dannemann AndersenCEO & Executive Director · born 1963
- Mr. Cellan DaviesHead of Marketing
- Mr. Mark Kingsley CollingbourneSecretary · born 1966